Business Context and Reporting Period
This Form 8-K Current Report was filed by Omeros Corporation on January 28, 2015, regarding a material definitive agreement entered into on that date. The filing details a public offering of common stock and pre-funded warrants.
Key Financial Metrics
The filing does not provide historical revenue, profit, cash flow, margins, or debt metrics. The primary financial data relates to the capital raise:
- Common Stock Sold: 2,995,506 shares at $20.03 per share.
- Pre-Funded Warrants Sold: 749,250 warrants at $20.02 per warrant.
- Optional Shares: Underwriters exercised the full 30-day option to purchase an additional 449,325 shares.
- Net Proceeds: Approximately $79.1 million after underwriting discounts and offering expenses.
- Expected Closing Date: February 3, 2015.
Material Changes
The filing reports the entry into an underwriting agreement with Cowen and Company, LLC. This transaction represents a significant increase in the company's equity capital and outstanding share count. The filing does not provide comparative financial data to quantify changes in operating performance versus prior periods.
Guidance, Outlook, and Risks
Management Commentary: The offering was priced and announced via a press release on January 29, 2015. The securities were registered under a shelf registration statement (Form S-3) effective January 16, 2015.
Terms and Contingencies:
- Warrant Terms: Pre-funded warrants have an exercise price of $0.01, are exercisable immediately, and expire on February 3, 2022.
- Ownership Limitations: Warrants cannot be exercised if the holder would beneficially own more than 4.99% of outstanding shares, unless a 61-day notice is provided to adjust this limit.
- Rights: Pre-funded warrants do not carry voting rights or other privileges of common stock until exercised.
- Closing Conditions: The transaction is subject to customary closing conditions.
Investor Verification Checklist
- Verify the final closing date of the offering (expected February 3, 2015) and confirm receipt of net proceeds.
- Review the final prospectus supplement filed on January 30, 2015, for complete risk factors and use of proceeds.
- Confirm the exact number of shares outstanding post-offering to assess dilution impact.
- Monitor the exercise of pre-funded warrants and any notices regarding the 4.99% beneficial ownership limitation.